PhoenixBio Co., Ltd. (JP:6190)
:6190
Want to see JP:6190 full AI Analyst Report?
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥315.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.78B
Enterprise Value¥1.18B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.54
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PXB‑mouse PlatformPhoenixBio’s proprietary PXB humanized‑mouse platform is a durable competitive asset: it creates high technical barriers, specialized expertise and customer lock‑in for preclinical liver/metabolism testing. This structural advantage supports recurring demand from pharma/biotech over multiple years.
Multiple Monetization StreamsThe company monetizes its platform across product sales, licensing/usage and fee‑for‑service studies. This revenue mix reduces single‑stream dependence, supports cross‑sell of services, and provides structural revenue diversification tied to ongoing drug development cycles.
Relatively Stable Balance SheetA healthy equity ratio and moderate leverage give PhoenixBio financial flexibility to fund platform maintenance, R&D and operations over the medium term. The balance sheet strength reduces immediate refinancing risk and supports strategic investments despite operating headwinds.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow constrains the company’s ability to self‑fund R&D, maintain facilities and scale services. Over 2–6 months this forces reliance on external financing or capital discipline, which can delay product development and weaken competitive positioning if unaddressed.
Negative EBIT/EBITDA MarginsNegative operating margins in 2025 indicate structural cost or pricing pressure versus peers. Without a durable margin recovery, PhoenixBio may struggle to convert its platform advantage into sustainable profits, limiting reinvestment capacity and increasing sensitivity to demand shocks.
Earnings Deterioration And Revenue StressA steep EPS decline signals material earnings volatility and impaired profitability that can persist across quarters. Coupled with reported revenue declines, this undermines cash‑flow predictability and restricts long‑term planning, making it harder to scale services and retain investor/partner confidence.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥315.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.78B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 21 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―